Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress
WOODCLIFF LAKE, N.J., Aug. 31, 2017 /PRNewswire/ -- Eisai Inc. will present data from its lenvatinib (marketed as Lenvima(®)) clinical trial program in four difficult-to-treat cancers at the European Society of Medical Oncology (ESMO) 2017 Congress taking place in Madrid, Spain, from Sept. 8-12. Additional data from the Company's oncology portfolio in key tumors, including advanced forms of breast and biliary tract cancer, among others, will also be presented during the conference.
"Our robust clinical research in various tumor types aims to further understand how lenvatinib may be used in additional patients, either as a part of a combination regimen with immunotherapy or as a monotherapy," said Alton Kremer, MD, PhD, Chief Clinical Officer and Chief Medical Officer, Oncology Business Group at Eisai. "The presentations at the ESMO 2017 Congress underscore Eisai's commitment to patients with difficult-to-treat cancers."
Presentations of interest include:
-- An analysis from the Phase 3 REFLECT study in patients with unresectable
hepatocellular carcinoma comparing health-related quality of life
outcomes and disease symptoms for those treated with lenvatinib to those
treated with sorafenib.
-- An analysis evaluating serum biomarkers in the REFLECT study will
also be presented.
-- Results from the cohort of patients with metastatic renal cell carcinoma
in the Phase 1b/2 Study 111 evaluating lenvatinib in combination with
pembrolizumab in approximately 250 patients with selected solid tumors.
-- Primary analysis results from a Phase 2 study of lenvatinib as a
second-line treatment in unresectable biliary tract cancer.
This release discusses investigational compounds that are not Food and Drug Administration (FDA)-approved and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any of these investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
The full list of Eisai presentations, including the time and location of each session, is included below.
Abstract Name Session (All times are CEST)
------------- ---------------------------
Lenvatinib Abstracts
--------------------
A phase 1b/2 trial of lenvatinib plus
pembrolizumab in Abstract #847O
patients With renal cell carcinoma Proffered Paper Session
Saturday, Sept. 9, 2017
10:15-10:45 a.m.
Location: Madrid Auditorium
C.H. Lee
--- --------
Health-related quality of life (HRQOL)
and disease Abstract #618O
symptoms in patients with unresectable
hepatocellular Proffered Paper Session
carcinoma (HCC) treated with lenvatinib
(LEN) or Sunday, Sept. 10, 2017
sorafenib (SOR) 12:00-12:30 p.m.
Location: Barcelona
Auditorium
A. Vogel
--- --------
Analysis of serum biomarkers (BM) in
patients (pts) from Abstract #LBA30
a phase 3 study of lenvatinib (LEN) vs
sorafenib (SOR) Proffered Paper Session
as first-line treatment for
unresectable hepatocellular Sunday, Sept. 10, 2017
carcinoma (uHCC) 11:45 a.m.-12:30 p.m.
Location: Barcelona
Auditorium
R.S. Finn
--- ---------
Comparing ITC results from lenvatinib
plus everolimus for Abstract #878P
second-line treatment of advanced/
metastatic renal cell Poster Display Session
carcinoma: crossover versus no
crossover Sunday, Sept. 10, 2017
1:15-2:15 p.m.
Location: Hall 8
A.S. Garib
--- ----------
Impact of duration of dose interruption
on the efficacy of Abstract #434PD
Poster Discussion Session
lenvatinib (LEN) in a Phase 3 study in
patients (pts) with Monday, Sept. 11, 2017
11 a.m.-12 p.m.
radioiodine refractory differentiated
thyroid cancer (RR-DTC) Location: Alicante Auditorium
M. Tahara
--- ---------
A Phase 2 study of lenvatinib (LEN)
monotherapy as Abstract #722P
Poster Display Session
second-line treatment in unresectable
biliary tract cancer: Saturday, Sept. 9, 2017
1:15-2:15 p.m.
primary analysis results Location: Hall 8
M. Ikeda
--- --------
Network meta-analysis (NMA) of
treatments for Abstract #707P
Poster Display Session
unresectable hepatocellular carcinoma
(uHCC) Saturday, Sept. 9, 2017
1:15-2:15 p.m.
Location: Hall 8
G. Tremblay
--- -----------
Eribulin Abstract
-----------------
Prospective observational study of
peripheral neuropathy Abstract #292P
in breast cancer patients treated with
eribulin Poster Display Session
Monday, Sept. 11, 2017
1:15-2:15 p.m.
Location: Hall 8
Y. Sakata
--- ---------
E7046 Abstract
--------------
Phase 1 study of E7046, a PGE2 receptor
EP-4 inhibitor Abstract #373PD
that targets immunosuppressive myeloid
cells in the Poster Discussion Session
tumor microenvironment Saturday, Sept. 9, 2017
4:30-6 p.m.
Location: Alicante Auditorium
D.S. Hong
--- ---------
About Lenvima(® )(lenvatinib)
Lenvima(®) (lenvatinib) is a kinase inhibitor that is indicated for:
-- Differentiated Thyroid Cancer (DTC): single agent for patients with
locally recurrent or metastatic, progressive, radioactive
iodine-refractory DTC.
-- Renal Cell Cancer (RCC): in combination with everolimus for patients
with advanced RCC following one prior anti-angiogenic therapy.
Lenvatinib, discovered and developed by Eisai, is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1-3. Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4; the platelet derived growth factor receptor alpha (PDGFR ), KIT, and RET. The combination of lenvatinib and everolimus showed increased anti-angiogenic and anti-tumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone.
Important Safety Information
Warnings and Precautions
-- In DTC, hypertension was reported in 73% of patients on Lenvima vs 16%
with placebo (44% vs 4% grade >=3). In RCC, hypertension was reported in
42% of patients on Lenvima + everolimus vs 10% with everolimus alone
(13% vs 2% grade 3). Systolic blood pressure >=160 mmHg occurred in 29%
of patients, and 21% of patients had a diastolic blood pressure >=100
mmHg in the Lenvima + everolimus-treated group. Blood pressure should be
controlled prior to treatment and monitored throughout. Withhold dose
for grade 3 hypertension despite optimal antihypertensive therapy;
resume at reduced dose when controlled at grade <=2. Discontinue for
life-threatening hypertension
-- In DTC, cardiac dysfunction was reported in 7% of patients on Lenvima vs
2% with placebo (2% vs 0% grade >=3). In RCC, decreased ejection
fraction and cardiac failure were reported in 10% of patients on Lenvima
+ everolimus vs 6% with everolimus alone (3% vs 2% grade 3). Monitor for
signs/symptoms of cardiac decompensation. Withhold Lenvima for
development of grade 3 cardiac dysfunction until improvement to grade 0,
1, or baseline. Resume at reduced dose or discontinue based on severity
and persistence of cardiac dysfunction. Discontinue for grade 4 cardiac
dysfunction
-- In DTC, arterial thromboembolic events were reported in 5% of patients
on Lenvima vs 2% with placebo (3% vs 1% grade >=3). In RCC, arterial
thromboembolic events were reported in 2% of patients on Lenvima +
everolimus vs 6% with everolimus alone (2% vs 4% grade >=3). Discontinue
following an arterial thrombotic event. The safety of resuming Lenvima
after an arterial thromboembolic event has not been established, and
Lenvima has not been studied in patients who have had an arterial
thromboembolic event within the previous 6 months
-- Across clinical studies in which 1,160 patients received Lenvima
monotherapy, hepatic failure (including fatal events) was reported in 3
patients and acute hepatitis in 1 patient. In DTC, ALT and AST increases
(grade >=3) occurred in 4% and 5% of patients on Lenvima, respectively,
vs 0% with placebo. In RCC, ALT and AST increases (grade >=3) occurred
in 3% of patients on Lenvima + everolimus vs 2% and 0% with everolimus
alone, respectively. Monitor liver function before initiation, then
every 2 weeks for the first 2 months, and at least monthly thereafter
during treatment. Withhold dose for liver impairment grade >=3 until
resolved to grade 0, 1, or baseline. Resume at reduced dose or
discontinue based on severity/persistence of hepatotoxicity. Discontinue
for hepatic failure
-- In DTC, proteinuria was reported in 34% of patients on Lenvima vs 3%
with placebo (11% vs 0% grade 3). In RCC, proteinuria was reported in
31% of patients on Lenvima + everolimus vs 14% with everolimus alone (8%
vs 2% grade 3). Monitor for proteinuria before and during treatment.
Withhold dose for proteinuria >=2 g/24 h. Resume at reduced dose when
proteinuria is <2 g/24 h. Discontinue for nephrotic syndrome
-- In RCC, diarrhea was reported in 81% of patients on Lenvima + everolimus
vs 34% with everolimus alone (19% vs 2% grade >=3). Initiate prompt
medical management for the development of diarrhea. Monitor for
dehydration. Withhold dose for diarrhea grade >=3. Resume at a reduced
dose when diarrhea resolves to grade 1 or baseline. Permanently
discontinue Lenvima for grade 4 diarrhea despite medical management
-- In DTC, events of renal impairment were reported in 14% of patients on
Lenvima vs 2% with placebo (3% vs 1% grade >=3). In RCC, events of renal
impairment were reported in 18% of patients on Lenvima + everolimus vs
12% with everolimus alone (10% vs 2% grade >=3). Withhold Lenvima for
grade 3 or 4 renal failure/impairment. Resume at reduced dose or
discontinue, depending on severity/persistence of renal impairment.
Active management of diarrhea and any other gastrointestinal (GI)
symptoms should be initiated for grade 1 events
-- In DTC, events of GI perforation or fistula were reported in 2% of
patients on Lenvima vs 0.8% with placebo. In RCC, events of GI
perforation, abscess, or fistula (grade >=3) were reported in 2% of
patients on Lenvima + everolimus vs 0% with everolimus alone.
Discontinue in patients who develop GI perforation or life-threatening
fistula
-- In DTC, QT/QTc interval prolongation was reported in 9% of patients on
Lenvima vs 2% with placebo (2% vs 0% >500 ms). In RCC, QTc interval
increases >60 ms were reported in 11% of patients on Lenvima +
everolimus (6% >500 ms) vs 0% with everolimus alone. Monitor
electrocardiograms in patients with congenital long QT syndrome,
congestive heart failure, bradyarrhythmias, or patients taking drugs
known to prolong the QT interval. Monitor and correct electrolyte
abnormalities in all patients. Withhold dose for QTc interval
prolongation >500 ms. Resume at reduced dose when QTc prolongation
resolves to baseline
-- In DTC, hypocalcemia (grade >=3) was reported in 9% of patients on
Lenvima vs 2% with placebo. In RCC, hypocalcemia (grade >=3) was
reported in 6% of patients on Lenvima + everolimus vs 2% with everolimus
alone. Monitor blood calcium levels at least monthly and replace calcium
as necessary. Interrupt and adjust Lenvima as necessary
-- Across clinical studies in which 1,160 patients received Lenvima
monotherapy, reversible posterior leukoencephalopathy syndrome (RPLS)
was reported in 4 patients. Withhold Lenvima for RPLS until fully
resolved. Resume at reduced dose or discontinue based on the severity
and persistence of neurologic symptoms
-- Across clinical studies in which 1,160 patients received Lenvima
monotherapy, hemorrhage (grade >=3) was reported in 2% of patients. In
DTC, hemorrhagic events occurred in 35% of patients on LENVIMA vs 18%
with placebo (2% vs 3% grade >=3). There was 1 fatal intracranial
hemorrhage case among 16 patients who received Lenvima and had central
nervous system metastases at baseline. The most frequently reported
hemorrhagic event was epistaxis (11% grade 1, 1% grade 2).
Discontinuation due to hemorrhagic events occurred in 1% of patients on
Lenvima. In RCC, hemorrhagic events occurred in 34% of patients on
Lenvima + everolimus vs 26% with everolimus alone (8% vs 2% grade >=3).
The most frequently reported hemorrhagic event was epistaxis (23% for
Lenvima + everolimus vs 24% with everolimus alone). There was 1 fatal
cerebral hemorrhage case. Discontinuation due to hemorrhagic events
occurred in 3% of patients on Lenvima + everolimus. Consider the risk of
severe or fatal hemorrhage associated with tumor invasion/infiltration
of major blood vessels (eg, carotid artery). Withhold Lenvima for the
development of grade 3 hemorrhage until resolved to grade 0 or 1. Resume
at reduced dose or discontinue based on severity/persistence of
hemorrhage. Discontinue for grade 4 hemorrhage
-- In DTC patients with normal baseline thyroid-stimulating hormone (TSH),
elevation of TSH level above 0.5 mU/L was observed postbaseline in 57%
of patients on Lenvima vs 14% with placebo. In RCC, grade 1 or 2
hypothyroidism occurred in 24% of patients on Lenvima + everolimus vs 2%
with everolimus alone. In RCC patients with normal or low TSH at
baseline, elevation of TSH was observed postbaseline in 60% of patients
on Lenvima + everolimus vs 3% with everolimus alone. Monitor thyroid
function before initiation of and at least monthly throughout treatment.
Treat hypothyroidism according to standard medical practice to maintain
a euthyroid state
-- Lenvima can cause fetal harm when administered to a pregnant woman.
Advise females of reproductive potential to use effective contraception
during treatment with Lenvima and for at least 2 weeks following
completion of therapy
Adverse Reactions
-- In DTC, the most common adverse reactions (>=30%) observed in
Lenvima-treated patients vs placebo-treated patients were hypertension
(73% vs 16%), fatigue (67% vs 35%), diarrhea (67% vs 17%),
arthralgia/myalgia (62% vs 28%), decreased appetite (54% vs 18%), weight
decrease (51% vs 15%), nausea (47% vs 25%), stomatitis (41% vs 8%),
headache (38% vs 11%), vomiting (36% vs 15%), proteinuria (34% vs 3%),
palmar-plantar erythrodysesthesia syndrome (32% vs 1%), abdominal pain
(31% vs 11%), and dysphonia (31% vs 5%)
-- In DTC, adverse reactions led to dose reductions in 68% of patients
receiving Lenvima and in 5% of patients receiving placebo; 18% of
patients discontinued Lenvima and 5% discontinued placebo for adverse
reactions. The most common adverse reactions (>=10%) resulting in dose
reductions of Lenvima were hypertension (13%), proteinuria (11%),
decreased appetite (10%), and diarrhea (10%); the most common adverse
reactions (>=1%) resulting in discontinuation of Lenvima were
hypertension (1%) and asthenia (1%)
-- In RCC, the most common adverse reactions (>30%) observed in patients
treated with Lenvima + everolimus vs everolimus alone were diarrhea (81%
vs 34%), fatigue (73% vs 40%), arthralgia/myalgia (55% vs 32%),
decreased appetite (53% vs 18%), vomiting (48% vs 12%), nausea (45% vs
16%), stomatitis/oral inflammation (44% vs 50%), hypertension/increased
blood pressure (42% vs 10%), peripheral edema (42% vs 20%), cough (37%
vs 30%), abdominal pain (37% vs 8%), dyspnea/exertional dyspnea (35% vs
28%), rash (35% vs 40%), weight decreased (34% vs 8%), hemorrhagic
events (32% vs 26%), and proteinuria/urine protein present (31% vs 14%).
The most common serious adverse reactions (>=5%) were renal failure
(11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea
(5%), vomiting (5%), and dyspnea (5%)
-- In RCC, adverse reactions led to dose reductions or interruption in 89%
of patients receiving Lenvima + everolimus and in 54% of patients
receiving everolimus alone. The most common adverse reactions (>=5%)
resulting in dose reductions in the Lenvima + everolimus-treated group
were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting (6%),
nausea (5%), and proteinuria (5%). Treatment discontinuation due to an
adverse reaction occurred in 29% of patients in the Lenvima +
everolimus-treated group and in 12% of patients in the
everolimus-treated group
Use in Specific Populations
-- Because of the potential for serious adverse reactions in nursing
infants, advise women to discontinue breastfeeding during treatment
-- Lenvima may result in reduced fertility in females of reproductive
potential and may result in damage to male reproductive tissues, leading
to reduced fertility of unknown duration
For more information about Lenvima, click here for the full Prescribing Information.
About HALAVEN(®) (eribulin mesylate) Injection
HALAVEN(®) (eribulin mesylate) is a microtubule dynamics inhibitor indicated for the treatment of patients with:
-- Metastatic breast cancer who have previously received at least two
chemotherapeutic regimens for the treatment of metastatic disease. Prior
therapy should have included an anthracycline and a taxane in either the
adjuvant or metastatic setting.
-- Unresectable or metastatic liposarcoma who have received a prior
anthracycline- containing regimen.
Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. First in the halichondrin class, HALAVEN is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.
Important Safety Information
Warnings and Precautions
Neutropenia: Severe neutropenia (ANC <500/mm(3)) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.
Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.
Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.
QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.
Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (>=25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).
In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (>=25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (>=5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each).
Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.
Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.
For more information about HALAVEN, click here for the full Prescribing Information.
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, manufacturing and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Contacts: Media Inquiries Investor Inquiries
Laurie Landau Ivor Macleod
Eisai Inc. Eisai Inc.
(201) 746-2510 (201) 746-2660
View original content:http://www.prnewswire.com/news-releases/eisai-to-present-new-clinical-data-in-variety-of-advanced-cancers-at-the-esmo-2017-congress-300512554.html
SOURCE Eisai Inc.
